iRhythm Technologies (IRTC) Projected to Release Quarterly Earnings on Thursday

iRhythm Technologies (NASDAQ:IRTC) is projected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect iRhythm Technologies to announce earnings of ($0.04) per share and revenue of $219.3280 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

iRhythm Technologies Trading Up 6.4%

Shares of iRhythm Technologies stock opened at $124.66 on Tuesday. The company has a 50 day simple moving average of $113.99 and a two-hundred day simple moving average of $125.41. iRhythm Technologies has a 1 year low of $100.85 and a 1 year high of $212.00. The company has a debt-to-equity ratio of 4.03, a current ratio of 5.17 and a quick ratio of 4.98. The firm has a market cap of $4.10 billion, a PE ratio of -144.95 and a beta of 1.30.

Insiders Place Their Bets

In other iRhythm Technologies news, Director Abhijit Y. Talwalkar bought 5,312 shares of the company’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $10.71 per share, for a total transaction of $56,891.52. Following the completion of the transaction, the director directly owned 25,611 shares of the company’s stock, valued at approximately $274,293.81. This represents a 26.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.98% of the stock is owned by company insiders.

Institutional Trading of iRhythm Technologies

A number of large investors have recently modified their holdings of the company. US Bancorp DE raised its holdings in iRhythm Technologies by 7.8% in the 3rd quarter. US Bancorp DE now owns 1,042 shares of the company’s stock valued at $179,000 after acquiring an additional 75 shares during the last quarter. State of Wyoming lifted its position in shares of iRhythm Technologies by 16.0% during the fourth quarter. State of Wyoming now owns 616 shares of the company’s stock worth $109,000 after purchasing an additional 85 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in iRhythm Technologies by 0.3% in the third quarter. Alliancebernstein L.P. now owns 37,489 shares of the company’s stock valued at $6,448,000 after purchasing an additional 95 shares during the period. California State Teachers Retirement System grew its holdings in iRhythm Technologies by 0.3% during the 2nd quarter. California State Teachers Retirement System now owns 28,917 shares of the company’s stock worth $4,452,000 after acquiring an additional 99 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in shares of iRhythm Technologies by 4.3% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 2,472 shares of the company’s stock valued at $439,000 after acquiring an additional 102 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on IRTC. Truist Financial decreased their target price on shares of iRhythm Technologies from $174.00 to $160.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Weiss Ratings upgraded shares of iRhythm Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. The Goldman Sachs Group decreased their price objective on shares of iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. JPMorgan Chase & Co. lowered their price target on iRhythm Technologies from $215.00 to $175.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, Wall Street Zen raised iRhythm Technologies from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, iRhythm Technologies has an average rating of “Moderate Buy” and an average target price of $184.71.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.